Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways

Pharmacology

Volumn 80, Issue 1, 2007, Pages 57-64

  Bao, Yan ^a   Jia, Ru Han ^a   Yuan, Jun ^a   Li, Jing ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Monocyte chemoattractant protein 1; Nuclear factor B; Reactive oxygen species; Rosiglitazone

Indexed keywords

ALBUMIN; COPPER ZINC SUPEROXIDE DISMUTASE; CREATININE; GLUCOSE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; MALONALDEHYDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME ASSAY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; HYPOGLYCEMIC AGENTS; MALE; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; THIAZOLIDINEDIONES;

EID: 34347325071     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103232     Document Type: Article

References (36)

1. Salahudeen AK, Kanji V, Reckelhoff JF, Schmidt AM: Pathogenesis of diabetic nephropathy: a radical approach. Nephrol Dial Transplant 1997;12:664-668.
2. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H: Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003;14:S241-S245.
3. Ha H, Lee HB: Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int Suppl 2000;77:S19-S25.
4. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
5. Rovin BH, Dickerson JA, Tan LC, Hebert CA: Activation of nuclear factor-κB correlates with MCP-1 expression by human mesangial cells. Kidney Int 1995;48:1263-1271.
6. Marumo T, Schini-Kerth VB, Busse R: Vascular endothelial growth factor activates nuclear factor-κB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999;48:1131-1137.
7. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K: Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000;58:684-690.
8. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
9. Sreenan S, Sturis J, Pugh W, Burant CF, Polonsky KS: Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol 1996;271:E742-E747.
10. Alarcon de la Lastra C, Sanchez-Fidalgo S, Villegas I, Motilva V: New pharmacological perspectives and therapeutic potential of PPAR-γ agonists. Curr Pharm Des 2004;10:3505-3524.
11. Villegas I, Martin AR, Toma W, de la Lastra CA: Rosiglitazone, an agonist of peroxisome proliferator-activated receptor-γ, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. Eur J Pharmacol 2004;505:195-203.
12. Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiemermann C, Fantozzi R: Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-α agonist WY14643. Free Radic Biol Med 2006;41:579-589.
13. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000;49:1022-1032.
14. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI: Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003;17:7-12.
15. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB: Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001;59:1899-1910.
16. Yoshida K, Kohzuki M, Xu HL, Wu XM, Kamimoto M, Sato T: Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure. J Hypertens 2001;19:503-510.
17. Van Bamme B, Koudstaal J: Measuring glomerular diameters in tissue sections. Virchows Arch A Pathol Anat Histol 1976;369:283-291.
18. Kim Y, Fischer SM: Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues. J Biol Chem 1998;273:27686-27694.
19. Ha H, Kim KH: Future of interventions in diabetic nephropathy: antioxidants. Perit Dial Int 1999;19(suppl 2):S228-S233.
20. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M: Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 2003;14:S250-S253.
21. Guijarro C, Egido J: Transcription factor-κB and renal disease. Kidney Int 2001;59:415-424.
22. 2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 2001;50:2114-2125.
23. Nishio Y, Kashiwagi A, Taki H, Shinozaki K, Maeno Y, Kojima H, Maegawa H, Haneda M, Hidaka H, Yasuda H, Horiike K, Kikkawa R: Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats. Diabetes 1998;47:1318-1325.
24. Hofmann MA, Schiekofer S, Isermann B, Kanitz M, Henkels M, Joswig M, Treusch A, Morcos M, Weiss T, Borcea V, Abdel Khalek AK, Amiral J, Tritschler H, Ritz E, Wahl P, Ziegler R, Bierhaus A, Nawroth PP: Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 1999;42:222-232.
25. Ding H, Li F, Xu M, Deng Y, Deng Q, Zhu Z, Cheng H, Fu Z, Wang Y: The effect of inhibiting nuclear factor-κB on the diabetic nephropathy (in Chinese). Zhonghua Nei Ke Za Zhi 2002;41:605-609.
26. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998;391:79-82.
27. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P: Evidence for a potent anti-inflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-2735.
28. Rosenberger J, Petrovics G, Buzas B: Oxidative stress induces proorphanin FQ and proenkephalin gene expression in astrocytes through p38- and ERK-MAP kinases and NF-κB. J Neurochem 2001;79:35-44.
29. Squadrito F, Minutoli L, Esposito M, Bitto A, Marini H, Seminara P, Crisafulli A, Passaniti M, Adamo EB, Marini R, Guarini S, Altavilla D: Lipid peroxidation triggers both c-Jun N-terminal kinase and extracellular-regulated kinase activation and neointimal hyperplasia induced by cessation of blood flow in the mouse carotid artery. Atherosclerosis 2005;178:295-302.
30. Ihm CG, Park JK, Hong SP, Lee TW, Cho BS, Kim MJ, Cha DR, Ha H: A high glucose concentration stimulates the expression of monocyte chemotactic peptide-1 in human mesangial cells. Nephron 1998;79:33-37.
31. Sassy-Prigent C, Heudes D, Mandet C, Belair MF, Michel O, Perdereau B, Bariety J, Bruneval P: Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000;49:466-475.
32. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H: Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003;52:2586-2593.
33. Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R: Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003;63:209-216.
34. Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P: Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action? J Clin Endocrinol Metab 2001;86:3250-3256.
35. Wada K, Nakajima A, Blumberg RS: PPAR-γ and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med 2001;7:329-331.
36. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF, Auwerx J: Attenuation of colon inflammation through activators of the retinoid X receptor/peroxisome proliferator-activated receptor-γ heterodimer. A basis for new therapeutic strategies. J Exp Med 2001;193:827-838.